Biophan Technologies, Inc.Company Overview and Update

Michael Weiner, CEOStephens 2005 Nanotechnology Investors Conference

April 6, 2005

Cautionary Statement

Certain statements included in this presentation may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this presentation should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference.  The forward-looking statements contained herein are made only as of the date of this presentation, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Biophan’s Mission• Enable over $12 billion worth of medical devices

shipping annually safe for use with MRI, and imageable. Many are not:– Guidewires, catheters, endoscopes, biopsy

needles– Pacemakers, defibrillators, neurostimulators,

drug pumps (safety issues, also imaging issues), pain control devices

– Stents, embolism clips, aneurysm clips, artificial hips, knees, most other orthopedics

• Bring other innovations for competitive advantage to biomedical device and pharmaceutical companies.

Biophan’s Solutions

• MRI Safety: (many products contraindicated)– RF filter from Johns Hopkins (heating)

– “Anti-Antenna” lead design (heating & induced voltages)

– MRI Safe non-magnetic motor

• Nanomagnetic particle technologies– Minimize image artifacts

– Makes catheters, guidewires, stents, etc. visible under MRI

– Contrast agents

– Drug Delivery

PROTECTED, PROTECTED!• Technologies covered by

– 114 U.S. Patents

• 36 ISSUED

• 72 pending or allowed

• Owned by Biophan or licensed exclusively to Biophan for the medical market

• Plus many International patents

SE coronal image of 3 aluminum wires (1/32”). Wire (3) is uncoated.

1 2 3

Biophan’s thin-film

nanomagnetic

particle coating

technology provides

a controllable,

“magnetic” signal

capable of creating

an image of the

coated device.

#3 is uncoated.

MRI Device Imaging

Making Stents Imageable

• Seeing blockage of stents has required an invasive procedure

• Stents imageable under MRI would be competitively advantaged

• Nanoset has a nanomagnetic particle, thin film coating

• AMRIS, now Biophan-Europe, has a “retrofit” solution

• Both solutions are PATENTED!

Implications

• Impact the $5+ billion stent market

• Help manufacturers make pacemakers, defibrillators, neurostimulators safe, and imageable – competitive advantage to our licensees

• Make guidewires, catheters, endoscopes, biopsy needles safe and image compatible

• Opens the field of interventional medicine under MRI (currently only X-Ray/Fluoroscopy)

Biothermal Battery

• Goal: To provide a long-lived electrical power system for implanted medical devices– Powered by body heat differential.

• Batteries are a $500 million market, sell for $100 to $225 each in the pacemaker, defibrillator and drug pump markets

• Sold to same customers who need MRI safety

• Nanomaterials brings this capability within striking distance. We hold issues and pending patents

Agreement with NASA

• Announced on August 17th a deal with NASA Ames Research Center for Nanotechnology to jointly develop the biothermal battery– NASA wants technology for their long duration manned

MARS mission for biosensing and miniature therapeutic devices

– Biophan gets commercial rights to jointly developed and NASA developed technology

– Nanotechnology and materials science advances makes the biothermal battery possible

• Non-Magnetic• MRI-Safe and

Imageable • Greater efficiency• Enables precision

20 nm movements• Ideal for drug

pumps, cryogenic applications, implantables

• Biophan holds worldwide medical distribution rights, + equity

Substrate

Polymer Coating

Nanomagnetic layer

Con

trol

led

Mag

netic

Fie

ldDrug bound to NMP carrier

Con

trol

led

Mag

netic

Fie

ld A

Con

trol

led

Mag

netic

Fie

ld B

Particle type ADrug AParticle type BDrug B

Surface Elution on Demand

Reloading Drug Eluting Coatings

Substrate

Polymer Coating

Concentration G

radient

Controlled

Magnetic F

ield

Drug Molecules

Drug bound to NMP carrier

Nanomagnetic layer

Guided Drug Delivery

Solid tumor

Apply magnetic field to concentrate particles

Modulate field to release drug from particles

Inject NMPs IV,NMP will circulate through the blood stream

Other options for targeting:1 - Direct injection into tumor site2 - Coating NMP with antibodies to target tumor

Markets

• Medical devices (safe and/or image): $12 billion

• Battery: $500 million

• Contrast Agents: $800 million

• Drug Pumps: $1 billion

• Drug Delivery: $40 billion– Once deal is underway, patents and annuity streams can

last a long time;

– We anticipate money on signing, in development; plus milestones, royalties, high margin components

Business Model

• Offering our customers competitive advantage– Through proprietary solutions that can gain

marketshare for them– FDA approval is pursued by the customer– Marketing and distribution of the final device is

their responsibility• We sell high margin components and develop

annuities for our shareholders

Relationship With Boston Scientific

• Joint development agreement, originally entered into November, 2003

• Recently moved to second and third phase, and has expanded to multiple products

• Reached agreement on term sheet, working on final contract phase

Summary Financial Information

• Share Price (04.6.05): $3.00• 52-Week High: $3.50• 52 Week Low: $0.46• Shares Outstanding: 74 million• Float: 58 million• Market Cap: $222 million• Average Daily Volume: 1,023,272

BIOPHAN (OTCBB: BIPH)

Management• Stu MacDonald, VP R&D – formerly VP R&D at J&J

division, with a 400 person organization• Jeff Helfer, VP Engineering – formerly Dir. Of

Engineering at the same J&J division• John Lanzafame, President, Nanolution Division –

former President STS Biopolymers, acquired by Angiotech (ANPI)

• Robert Wood, VP Finance, Treasurer, Secretary, and CFO – CPA in public and private firms

• Michael Friebe, Ph.D. • Andreas Melzer, MD

Biophan (OTC: BIPH)

We don’t make medical devices; We make them safe, and imageable, for MRI

And other competitive advantages for our customers

Four of our six technologies are based on nanotechnology

WWW.BIOPHAN.COM